Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).

Pautier, Patricia

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). [electronic resource] - The oncologist 2012 - 1213-20 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1549-490X

10.1634/theoncologist.2011-0467 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Deoxycytidine--analogs & derivatives
Disease-Free Survival
Docetaxel
Dose-Response Relationship, Drug
Female
France--epidemiology
Granulocyte Colony-Stimulating Factor--therapeutic use
Humans
Leiomyosarcoma--drug therapy
Lenograstim
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Recombinant Proteins--therapeutic use
Taxoids--therapeutic use
Uterine Neoplasms--drug therapy
Gemcitabine